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Langerhans cells play a key role in contact hypersensitivity
reactions. The application of haptens on the skin leads
to many modifications of these cells, including the
increase of major histocompatibility complex II expres-
sion, allogeneic stimulation potency, and migration
towards lymph nodes to activate T cells. Moreover, it
has been shown that Langerhans cells cultured in vitro are
able to prime naı¨ve T cells in response to hapten contact.
From CD341 progenitors present in cord blood, we
generated dendritic cells of which some presented the
phenotypic markers of Langerhans cells. We show that
these cells are able to sensitize syngeneic naı¨ve
(CD45RAF) T cells to haptens such as trinitrophenyl
conjugate of trinitrobenzene sulfonic acid (TNP) and
fluoroscein isothiocyanate. The response to TNP is
higher than to fluoroscein isothiocyanate, whereas
sodium dodecyl sulfate, an irritant molecule used as a
control, never caused this effect. Phenotypic analysis of
Dendritic cells (DC) derived from stem cells originatingfrom bone marrow represent the most potent antigen-presenting cells for the initiation of a primary T cellresponse (Steinman, 1991). Epidermal Langerhans cells,which are DC localized in the skin, are able to take
up and process antigens. These cells have been shown to play a key
role in the development of contact hypersensitivity reactions. In vivo,
24 h after the application of haptens to the skin, a significant percentage
of Langerhans cells in the epidermis increased surface class II major
histocompatibility complex antigen expression. These cells exhibited
enhanced syngeneic and allogeneic T cell stimulatory function, left the
skin, and migrated to the draining lymph nodes in order to activate
(sensitize) specific T cells (for review see Teunissen, 1992). Moulon
et al (1993) have shown that in vitro cultured, but not freshly prepared
human Langerhans cells were able to induce a primary proliferative
response to trinitrophenyl conjugate of trinitrobenzene sulfonic acid
(TNP). This latter result supports the idea of a functional in vitro
Manuscript received May 3, 1997; revised November 30, 1997; accepted for
publication December 10, 1997.
Reprint requests to: Dr. Claude Vincent, INSERM Unite´ 346, Laboratoire
de Recherche Peau Humaine et Immunite´, Hoˆpital Edouard Herriot, 69437
Lyon Cedex 03, France.
Abbreviations: BB, Bandrowski’s base; MLR, mixed lymphocyte reaction;
PPDA, p-phenylenediamine base; TNP, trinitrophenyl conjugate of trinitroben-
zene sulfonic acid.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
348
cellular suspensions and experiments of cell sorting lead
to the conclusion that only CD1aF cells are able to induce
a primary response of syngeneic T cells to TNP or
fluoroscein isothiocyanate. Furthermore, we have shown
a close relationship between the differentiation state of
dendritic cells and their ability to prime T lymphocytes.
Dendritic cells are able to present haptens in an efficient
manner between day 10 and 14 of culturing CD34F
progenitors, whereas they were efficient in presenting
alloantigens from day 6 until after day 20. This dissoci-
ation suggests the need of an active metabolic process
for hapten presentation in the direct treatment of dend-
ritic cells with haptens. This model of hapten presentation
was used for a panel of fragrance molecules and other
molecules considered as weaker haptens than TNP and
fluoroscein isothiocyanate. Key words: chemical haptens/
human dendritic cells/in vitro model/primary response. J Invest
Dermatol 110:348–352, 1998
maturation of human Langerhans cells characterized by the acquisition
of most of the features of lymphoid DC (Picut et al, 1988; Romani
et al, 1989). Indeed, it has been suggested that intraepidermal Langerhans
cells are ‘‘immature’’ and that cultured Langerhans cells may represent
Langerhans cells that have migrated to regional lymph nodes (Streilein
and Grammer, 1989; Pure´ et al, 1990). Earlier reports have identified
progenitors of DC in human bone marrow, in cord blood, and in
peripheral blood. At the present time, it is possible to generate DC by
culture of CD341 progenitor cells isolated from bone marrow, cord
blood, or peripheral blood (Reid et al, 1990, 1992; Caux et al, 1992;
Strunk et al, 1996; Rosenzwajg et al, 1996). According to the
differentiation conditions some of the DC have characteristics of
Langerhans cells, in particular the presence of Birbeck granules (Caux
et al, 1995). Our aim was to determine under what conditions these
Langerhans cell-like DC generated from CD341 progenitors isolated
from cord blood are able to sensitize in vitro autologous T cells, in
order to establish a model for the study of the primary T cell response.
MATERIALS AND METHODS
Purification and culture of cord blood CD34F hematopoietic progenitor
cells Cord blood was collected according to institutional guidelines during
normal full-term deliveries. Mononuclear cells were isolated by flotation on
Ficoll-Paque (Pharmacia, Biotech, Uppsala, Sweden). CD341 cells were purified
by immunomagnetic selection with mini-MACS (Myltenyi-Biotec, GmbH,
Bergisch Gladbach, Germany). This procedure regularly gave a suspension with
more than 95% CD341 cells. Isolated progenitors were cultured according to
the method described by Caux et al (1992). They were cultured in RPMI 1640
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(GIBCO-BRL, Grand Island, NY) containing glutamax-1, 25 mM HEPES,
supplemented with 10% heat-inactivated fetal calf serum (GIBCO-BRL),
5 3 10–5 M 2ME (Sigma, St. Louis, MO), antibiotics (PSF, Sigma), and 200 U
of human recombinant granulocyte-macrophage colony-stimulating factor
(GM-CSF, specific activity 2 3 106 U per mg, kindly provided by Schering-
Plough Laboratories, Dardilly, France) per ml and 50 U of recombinant human
tumor necrosis factor-α (specific activity, 2 3 107 U per mg: Genzyme, Boston,
MA) per ml. Mature DC were harvested at day 12–14 and the phenotype
determined with a panel of monoclonal antibodies (MoAb).
Purification of cord blood and adult peripheral blood T
cells Mononuclear cells were isolated from adult peripheral blood or cord
blood by flotation on Ficoll-Paque, and then depleted of adherent cells by
overnight culture on plastic surface. T cells were purified by rosetting with
aminoethylisothiouronium bromide (AET)-treated sheep erythrocytes followed
by Ficoll-Paque flotation. T cells were frozen at 10 3 106 cells per vial in
RPMI 1640 with 30% fetal calf serum and 10% dimethyl sulfoxide.
In some experiments, T lymphocytes were fractionated according to their
CD45 status, after labeling with anti-CD45RA (B-C15) or CD45RO (UCHL1)
MoAb from Diaclone (Besanc¸on, France). Cells were purified by immunomag-
netic selection with mini-MACS using a second anti-mouse IgG antibody
conjugated with paramagnetic microbeads.
Chemical tests We used 2,4,6-trinitrobenzene sulfonic acid (Sigma) and
fluorescein isothiocyanate (FITC, Sigma), which are known as strong contact
allergens, a weaker sensitizing agent, p-phenylenediamine base (PPDA, Sigma)
and its oxidation product, Bandrowski’s base (BB, ICN, Costa Mesa, CA),
several fragrance materials with low contact sensitizing potency 3,7-dimethyl-
6-octenal (citronellal, Sigma), and 3-acetyl-7-[beta-D-glucopyranosyloxy]
(coumarin, Sigma). An irritant, sodium dodecyl sulfate (SDS, Sigma), was used
as a control. All chemicals were used in aqueous solutions. Coumarin had been
previously solubilized in ethanol, and BB in dimethyl sulfoxide (Sigma). To
circumvent problems related to the toxicity of trinitrobenzene sulfonic acid and
FITC, antigen-presenting cells were haptenated before they were cultured with
T cells. Modification of the antigen-presenting cells with the TNP was
performed according to the method of Shearer (1974). Cell pellets were
resuspended in Hank’s balanced salt solution containing 5 mM trinitrobenzene
sulfonic acid. FITC modifications were performed in the same way with Hank’s
balanced salt solution containing 100 µg of the hapten per ml. Cells were
incubated with these haptens for 10 min at 37°C and then washed out
thoroughly. SDS at 10 µg per ml was used as a control of hapten specificity
and was added directly to cell cultures. Phytohemagglutinin and concanavalin
A were purchased from Wellcome Laboratories (Paris, France).
Phenotypic analysis and cell sorting Cells were washed with isotonic
NaCl/Pi buffer containing 1% bovine serum albumin (BSA) and 0.2% NaN3
(PBS/BSA/Azide). Cells (2.5 3 105) were incubated with 10 µl of labeled
MoAb for 30 min at 4°C. The MoAb used were CD1a (B-B5, IgG1) from
Diaclone; CD2 (IOT11, IgG1), CD3 (UCHT 1, IgG1), CD4 (IOT4, IgG2a),
CD8 (B9–11, IgG1), CD83 (HB15, IgG2 k), and HLA-DR (IOT2a, IgG2b)
from Immunotech (Marseilles, France); and CD14 (TU¨K4, IgG2 κ), CD19
(HD37, IgG2b), CD21 (1F8, IgG1 κ), CD25 (ACT-1, IgG1 κ), E-cadherin
(HECD-1, IgG1), and S-100 protein (polyclonal) from DakoPATTS (Glostrup,
Denmark). CD40 (Mab 104) was from Scherring Plough (Dardilly, France).
Anti-Lag MoAb (Langerhans-associated granule) was kindly provided by Kashih-
ara-Sawami (Kyoto, Japan). After two washes in PBS/BSA/Azide, cells were
fixed with 1% formaldehyde in PBS/BSA/Azide. Analysis was performed on a
FACScan flow cytometer (Becton Dickinson, Mountain View, CA). Cell size
was estimated by light diffraction at small angles (FSC). Using unlabeled
antibodies, we added a second step including a GAMIg-FITC or a GAMIg-
PE (Zymed Laboratories, San Francisco, CA).
For cell sorting experiments, cells were labeled with anti-CD1a MoAb and
paramagnetic microbeads conjugated with anti-mouse IgG in phosphate-
buffered saline with 10% fetal calf serum and 5 mM ethylenediamine tetraacetic
acid instead of PBS/BSA/Azide. CD1a1 cells were purified by immunomagnetic
selection with mini-MACS.
T cell proliferative assays Stimulator cells were cocultured with 105
allogeneic or autologous responder T cells in round-bottom, 96 well microtiter
plates in RPMI 1640 with 10% fetal calf serum (RPMI/FCS), in a humidified
atmosphere, 5% CO2 at 37°C. Triplicate cultures for each allergen concentration
were maintained for 3–6 d. Proliferation was assessed by addition of 1 µCi [3H]
methyl-thymidine per well (2 Ci per mmol, Amersham, France), 18 h before
harvesting. Incorporated thymidine was quantitated in a β-counter (Matrix 96,
Packard Instrument, Downers Grove, IL). Results are expressed as the mean
dpm 6 SD of triplicate cultures.
Table I. Phenotypic analysis of cord and peripheral blood
T lymphocytes, data are expressed as the mean K SD
Cord blood Peripheral blood
Control 1.41 6 2.35 1.56 6 2.56
T cell markers
CD2 95.1 6 5.15 96.1 6 2.22
CD3 89.0 6 4.08 87.9 6 2.27
CD4 64.1 6 9.99 61.6 6 9.77
CD8 30.2 6 8.50 29.9 6 5.05
CD45RA 85.2 6 1.66 51.2 6 21.0
CD45RO 15.4 6 3.75 57.9 6 10.1
B cell markers
CD19 0.66 6 1.14 1.82 6 0.40
CD21 18.4 6 2.77 13.2 6 11.3
CD40 9.06 6 8.39 28.2 6 7.19
Other cell markers
CD1a 12.9 6 18.0 1.10 6 0.08
CD14 6.60 6 8.95 14.1 6 12.3
CD25 5.95 6 1.84 7.47 6 3.52
DR 5.83 6 7.61 3.70 6 4.56
Figure 1. Cord blood T lymphocytes proliferate in response to
mitogens and alloantigens in the presence of various amounts of
accessory cells. d, culture with 12 d DC; s, culture with adherent
monocytes; u, control culture with T lymphocytes alone. Solid lines
correspond to addition of mitogen or allogeneic cells and dashed lines to
controls without mitogen or with autologous cells for MLR. With mitogenic
activation, DC were always autologous and a low dose of mitogen (0.5 µg
per ml) was used to ensure there was no proliferation of pure T cell
suspensions. Each point represents the mean of triplicate values. Three other
experiments were performed with identical results.
Endocytosis assay Cells were washed in RPMI/FCS. Tubes containing
0.2 3 106 cells were pelleted, and resuspended with 0.1 ml of RPMI/FCS
containing 1 mg of fluorescent-dextran (FITC-dextran 40,000 MW, D-1845;
Molecular Probes, Eugene, OR) per ml, or Lucifer Yellow (Lucifer Yellow
CH, L-1177; Molecular Probes). Some of the tubes were incubated at 37°C
and some at 0°C. After 15 min of incubation, the cells were washed four times
with ice-cold phosphate-buffered saline containing 1% fetal calf serum and
0.01% NaN3.
Fluorescence analysis was performed on a FACScan flow cytometer (Becton
Dickinson). Fluorescence after incubation at 0°C represented only the back-
ground level with Lucifer Yellow, but stained the membrane receptors with
FITC-dextran.
RESULTS
Characteristics of T lymphocytes isolated from umbilical cord
blood With the exception of the ratio of ‘‘naı¨ve’’ to ‘‘memory’’ cells,
T lymphocytes isolated from cord blood by AET rosettes had a
phenotype comparable with that of peripheral blood lymphocytes
isolated by the same method (Table I). In particular, the CD4/CD8
lymphocytes ratio was identical, and in three different preparations we
did not observe cells with double staining by CD4 and CD8.
These T cells possessed the molecules that allowed them to receive
the second signal from accessory cells after stimulation by mitogens
such as phytohemagglutinin or concanavalin A (Fig 1). As accessory
cells, we used mature, autologous DC at 12 d of culture or autologous
monocytes isolated by adherence. The first type of accessory cells were
more efficient and with only 50 cells a significant response was still
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Figure 2. DC taken at various intervals of differentiation induces
only low levels of autologous MLR. One thousand or 5000 DC (A and
B, respectively) were added to 1 3 105 lymphocytes isolated from the same
cord blood sample (s) or from another cord blood sample (d). Results
are expressed as the mean dpm 6 SD.
Figure 3. TNP or FITC treated DC activate lymphocytes. One
thousand or 5000 DC at day 12 (A and B, respectively) were used. DC
were treated with TNP (d), FITC (j), SDS (s), or medium (u). DC
were added to 1 3 105 lymphocytes isolated from the same cord blood.
observed. Cord blood T cells responded to allogeneic stimulation
(Fig 1), a high level of response was observed with DC and a low but
significant level with allogeneic adherent monocytes. As the control,
we used autologous DC and adherent monocytes; both types of cells
induced a low but significant level of response, therefore suggesting a
certain degree of contamination by the mother lymphocytes.
With the aim of a better quantitation of this autologous mixed
lymphocyte reaction (MLR) phenomenon, we tested the potency of
allogeneic and autologous generated DC according to their differenti-
ation state. As shown in Fig 2, which represents data collected over
10 different experiments, the autologous MLR remained rather low
in comparison with allogeneic MLR; furthermore, the effect was low
if only 1000 DC were used.
These results allowed us to investigate the induction of the primary
response to TNP or FITC using DC generated from CD341 cord
blood cells and T lymphocytes isolated from the same cord blood sample.
TNP or FITC modified DC induce in vitro a T cell primary
proliferative response DC were pulsed with TNP or FITC, then
washed thoroughly before being added to T lymphocytes from the
same cord blood sample. Addition of 1000 or 5000 pulsed DC to
0.1 3 106 lymphocytes induced a proliferative response peaking at day
4–5 (Fig 3). In most of the experiments, the response to TNP was
higher than to FITC, whereas SDS, an irritant molecule used as the
control, was never effective from 0.01 µg per ml up to 50 µg per ml;
higher doses induced cells lysis.
If one expresses the results as the proliferation index, calculated as
the ratio of the dpm value with hapten to the dpm value for untreated
DC, we can directly compare different experiments. TNP or FITC
modified DC induced a primary sensitization in 25 of 25 separate
experiments using different donors, the proliferation index varied
between 2 and 7 and was always statistically significant (Fisher exact
probability test; Siegel, 1956). These results show that DC generated
from CD341 cord blood cells were able to induce a primary response
in autologous T lymphocytes.
In two separate experiments, naı¨ve (CD45RA1) and memory
Figure 4. CD1a1 DC are responsible for T lymphocyte activation.
One thousand DC at day 12 were used as a total cell suspension (white
bars) or sorted by mini-MACS; the hatched bars represent the CD1a1 cell-
depleted suspension and the black bars represent the CD1a1 cell-enriched
suspension. Results are expressed as the mean dpm 6 SD.
(CD45RO1) T cells were used. The naı¨ve population proliferated to
the same extent as unfractionated T cells in response to DC treated
with TNP or FITC, whereas the memory cells proliferated to a lesser
extent (data not shown).
CD1aF DC were cells that induced priming of naı¨ve cord blood
syngeneic T cells to TNP or FITC The differentiation of CD341
cord blood cells leads to phenotypically heterogeneous cell cultures
containing variable proportions of CD1a1 cells. Double labeling with
anti-CD1a and anti-CD14 allowed us to control the enrichment of
the cell suspension and we calculated the relationship between the
proliferation index and the quality of the cell suspension. There was
no correlation between the amount of CD141 cells and the proliferation
index (r 5 –0.04); by contrast, the correlation was statistically significant
between CD1a1 cells and the proliferation index (r 5 0.54; p , 0.02).
As these results suggested that CD1a1 cells were the cells able to
induce priming of T lymphocytes for haptens, we isolated CD1a1 and
non-CD1a1 cells by mini-MACS.
In three separate experiments, isolation of CD1a1 cells resulted in
suspensions containing more than 80% CD1a1 cells, the unselected
population contained less than 20% CD1a1 cells but most of the
CD141 cells. As shown in Fig 4, it was clearly established that CD1a1
DC were the active cell population for priming of the T lymphocytes.
The capacity of DC to prime T lymphocytes is related to their
differentiation state Throughout the differentiation process that
results in mature DC with a dendritic morphology and specific markers
such as CD1a, CD83, Birbeck granules, Lag antigen, S 100 protein,
and E-cadherin, the morphology and the phenotype of the DC varied
(Fig 5A). The endocytic properties of the cells also varied throughout
the differentiation process (Fig 5B). We wished to verify at what stage
these cells became able to prime T lymphocytes. Figure 6 shows that
DC present TNP and FITC during a period comprised between day
12 and day 14. Before day 10, the potency of these cells was limited,
despite the presence of functional HLA-DR and accessory molecules
as indicated by the efficiency of the same cells in the phytohemagglutinin
or concanavalin A test and in MLR. At day 16, DC were no longer
able to prime T lymphocytes. The phenotypic analysis of the cell
suspension after day 14 revealed that DC remained present in the
suspension as indicated by CD83 labeling, although the CD1a marker
progressively disappeared from the cells.
In order to understand the loss of reactivity after day 14, CD1a1
cells were isolated at various time intervals after day 12 and treated
with chemical allergens. A proliferative response was observed after
day 14; however, the potency of CD1a1 cells decreased progress-
ively (Fig 7).
Activation of T cells by DC in the presence of weaker
sensitizing agents The proliferative response of T cells was tested
with various amounts of each chemical; the dose routinely used
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Figure 5. Kinetics of phenotype and endocytic properties modifications
of DC during the culture. (A) Modifications of the phenotype: d, CD1a;
s, CD83; and ∆, E-cadherin. (B) Modifications of the endocytic capacity:
e, endocytosis of Lucifer Yellow by micropinocytosis; u, endocytosis of
FITC-dextran by the mannose receptor; j, presence of the mannose
receptor at the cell membrane detected at 0°C.
Figure 6. DC capacity for T lymphocyte activation depends upon
the stimulating agent. DC were isolated at day 0, cultured in the presence
of GM-CSF and tumor necrosis factor-α for differentiation, and then used
at various time intervals. Each point represents the mean of triplicate values.
thereafter was the highest, nontoxic dose. We showed that PPDA,
a highly sensitizing agent in vivo, did not induce a significant
lymphoproliferative response, whereas BB, its oxidation product that
is the active agent in vivo, induced a proliferation in 10 of 10
separate experiments using different blood donors (Fig 8). The
other molecules did not induce a significant T cell response.
DISCUSSION
We have demonstrated that DC generated in vitro from cord blood
can activate autologous naı¨ve T lymphocytes isolated from cord
Figure 7. The capacity of CD1aF cells to induce the proliferative
response decreases after day 14. DC were fractionated by mini-MACS
according to their CD1a status; 1000 DC, activated with chemical hapten,
were used to activate T cells. s, Unfractionated cells; d, CD1a enriched
cells; u, CD1a depleted cells. (A) DC were treated with TNP; (B) DC
were treated with FITC.
Figure 8. Comparison of T cell activation by chemical haptens in
the presence of 5000 DC at day 12. Results are expressed as the
mean dpm 6 SD.
blood and can induce a primary response to haptens. It is clear
that this activation requires an additional process in comparison
with allogeneic activation. We have demonstrated that in vitro, a
maturation step follows the differentiation step. This system allowed
us to establish a model of in vitro priming of human naı¨ve T cells
to contact allergens.
Different models have already been described to investigate the
induction of contact hypersensitivity to haptens and low molecular
mass chemicals, some of them in vivo in animal models (Gerberick
et al, 1992; Kligman and Basketter, 1995) or in vitro (Hauser and
Katz 1990), others using isolated epidermal Langerhans cells (Moulon
et al, 1993; Krasteva et al, 1996) and more recently peripheral blood
monocytes differentiated with cytokines (Kobel et al, 1996).
The model proposed in this paper demonstrates positive prolifera-
tion with TNP, FITC, and BB in all experiments, whereas the
negative results with coumarin and citronellal are in accordance
with the negative results obtained by Krasteva et al (1996), and
those found in human predictive testing (Opdyke, 1975). PPDA is
considered as a strong sensitizer in all animal and human in vivo
predictive tests (Goodwin et al, 1981; Marzulli and Mailbach, 1974;
Basketter and Scholes, 1992); however, it did not produce a
significant proliferative response in our experiment, whereas BB
induced a primary sensitization. These results are in agreement with
the concept of a prohapten (Basketter and Liden, 1992; Krasteva
et al, 1993), PPDA being the prohapten and BB the immunogenic
hapten obtained in vivo after metabolic oxidation of PPDA. The
absence of response in our system suggests that DC are not able
to metabolize the prohapten in these conditions.
A portion of the DC obtained in vitro from CD341 progenitors
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resembled Langerhans cells in terms of their phenotypic characteristics
and their functional potency. Usually, the functional potency of
such cells is tested by MLR (Romani et al, 1994; Caux et al, 1995)
or antigenic presentation to antigen-specific T cell clones (Sallusto
and Lanzavecchia, 1994; Caux et al, 1995). Only a few reports
have presented results of antigenic activation of naı¨ve T cells; we
present data indicating that an in vitro test of primary response,
other than MLR, is needed for the follow-up of the mature DC
generation.
DC generated from cord blood, according to the method originally
published by Caux et al (1992), represent only a portion of the
cells generated. Some cells presented the characteristics of Langerhans
cells, others represented DC with characteristics of the dermal
dendrocyte or monocyte or other cell types. Our findings indicate
that the induction of a primary response is restricted to CD1a1
cells, whereas all cells are able to provide a costimulation signal to
mitogen treated T cells and to induce an MLR. We cannot
discriminate at present between Langerhans-like DC and other DC.
A most important fact is the observation of an activation potency
restricted to a time interval between the tenth and fourteenth day,
whereas cells were able to stimulate T lymphocytes in the presence
of mitogen or in MLR as soon as day 6 and after day 19. The
kinetics of potency parallel the kinetics of Langerhans-like DC
maturation, and the appearance of specific markers such as CD83,
E-cadherin, S-100 protein, Lag antigen, and Birbeck granules. The
loss of hapten presentation potency after day 14 may be related to
the decrease of endocytic potency of these cells, rather than to the
disappearance of DC as might be suspected by the low proliferating
capacity of DC after day 6–8. These findings suggest that an active
process, including perhaps internalization and processing, is required
after TNP or FITC molecule binding. Internalization of membrane
molecules has been shown after hapten treatment or hapten-carrier
contact with murine Langerhans cells (Becker et al, 1995; Lempertz
et al, 1996); however, if the need for processing is well established
with hapten-carrier complexes (Ma et al, 1994; Woods et al, 1995),
it remains controversial with hapten alone (Moulon et al, 1993).
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